© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
September 08, 2008
This review summarizes an important substudy of the Rate Control Versus Electrical Cardioversion (RACE) trial, which randomized 522 patients with atrial fibrillation (AF) to rate versus rhythm control treatment strategies and followed them for up to 2.3 years with a primary composite endpoint that included cardiovascular mortality, heart failure, thromboembolic complications, bleeding, severe adverse effects of anti-arrhythmic agents, and pacemaker implantation.
Simulation Software Could Improve Teenage ADHD Driver Safety
Local Approach Needed to Increase Hepatitis B Vaccinations in Indonesia
Study Finds Increased Risk of Psoriasis for Patients with Herpes Zoster